Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: doctor bob who wrote (337)	4/1/1998 2:59:00 AM
From: Jon Smith	Respond to of 1185

I realize I haven't been a part of this thread for very long, but I would like to offer my opinion. Reading through past news, it seems that NRT's style is to sign a deal, (licensing or otherwise) with the stipulation that the (purchaser) also makes an equity investment into the company. As they did when they signed with the Asian Pharma. Therefore, I would expect to see a major licensing agreement followed by an equity financing or a positioning from the open market by this "ghost" company they are currently negotiating with. I also agree with Paul about the FMI performance. Nortran is much further along in development than Forbes is, therefore I would expect to see Nortran gain a considerable value if the right deal is announced. My guess is $5.00 plus by May 1/98

To: doctor bob who wrote (337)	4/1/1998 4:45:00 AM
From: M. Boldo	Read Replies (2) \| Respond to of 1185

I have been told that Nortan deal is much bigger than anyone here could ever imagine. I won't give the name of the company they are speaking with but will say that they are a very reputable, worldwide pharmaceutical giant. I am also under the impression that along with an agreement for RSD921, Nortran have secured a major financing. And yes the value of this is much larger than the Forbes you speak of. I expect everyone will be very pleased with their stock holdings in the coming weeks. Regards, Michael